XNAS
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -2.00 | -1.92 | +4.00% | $4,000 | ✅ Beat | +0.21% | -3.31% | — |
| 2026-05-06 | Q1 2026 | -2.45 | -1.10 | +55.10% | $2,000 | ✅ Beat | +0.00% | -7.72% | -42.59% |
| 2026-03-12 |
| Q4 2025 |
| -2.20 |
| -7.68 |
| -249.09% |
| $6,000 |
| ❌ Miss |
| -9.38% |
| -16.17% |
| -9.63% |
| 2025-11-12 | Q3 2025 | -2.71 | -2.13 | +21.40% | $15,000 | ✅ Beat | — | — | — |
| 2025-08-12 | Q2 2025 | -2.90 | -2.89 | +0.34% | $8,000 | ✅ Beat | +0.00% | +2.46% | +25.83% |
| 2025-03-11 | Q4 2024 | -0.13 | -0.16 | -23.08% | $11,000 | ❌ Miss | +0.87% | -27.34% | -37.67% |
| 2024-11-07 | Q3 2024 | -0.20 | -0.14 | +30.00% | $34,000 | ✅ Beat | +0.00% | -9.84% | -26.23% |
| 2024-08-07 | Q2 2024 | -0.20 | -0.15 | +25.00% | $13,000 | ✅ Beat | +6.38% | -14.89% | -17.02% |
Showing last 8 quarters.